Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc. (Nasdaq: GYRE) is a commercial-stage biopharmaceutical company developing and commercializing small-molecule therapies for organ fibrosis and inflammatory diseases. Through its majority indirectly owned subsidiary, Gyre Pharmaceuticals, it sells medicines in China, including ETUARY®… From the company’s description.
Over the twelve months to Sep 30, 2026, Gyre Therapeutics, Inc. reported revenue of $123.66M, up 15.3% from a year earlier, and a net loss of $36.69M. Its operating margin was −28.1%, and operations used $23.16M in cash. In fiscal 2025, it reported revenue of $116.59M, up 10.2% from fiscal 2024, and net income of $9.88M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Gyre Therapeutics, Inc. does
In the company’s own words
Gyre Therapeutics, Inc. (Nasdaq: GYRE) is a commercial-stage biopharmaceutical company developing and commercializing small-molecule therapies for organ fibrosis and inflammatory diseases. Through its majority indirectly owned subsidiary, Gyre Pharmaceuticals, it sells medicines in China, including ETUARY® (pirfenidone) for idiopathic pulmonary fibrosis, Etorel® (nintedanib) for several fibrotic lung diseases, and Contiva® (avatrombopag) for thrombocytopenia associated with chronic liver disease and chronic idiopathic thrombocytopenia. Its development pipeline includes hydronidone for liver fibrosis, F573 for liver failure, F230 for pulmonary arterial hypertension, and F528 for chronic obstructive pulmonary disease; it is also studying pirfenidone for additional lung indications. The company combines its established Chinese commercial operations with U.S. clinical development activities. ETUARY® generated $106.1 million in sales in 2025, while Etorel® and Contiva® generated $4.6 million and $5.5 million, respectively, that year. Its website is https://www.gyretry.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1124105
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Gyre Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Gyre Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Gyre Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Gyre Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Gyre Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”